Ranbaxy Fraud Settlement Emphasizes Guilty Pleas, Downplays Exclusion
Executive Summary
Although pharmaceutical company settlements in the millions of dollars now seem customary, a guilty plea to seven felonies could signal aggressive government pursuit of manufacturing and data integrity concerns.
You may also be interested in...
FDA Employees Were ‘Granting Approval Without Knowing Why,’ Judge Rules In Ranbaxy Case
But court finds FDA has authority to correct its mistakes and revoke Ranbaxy’s tentative ANDA approvals
Ranbaxy Claims ‘Buyer’s Remorse’ Behind U.S. ANDA Moves
Suit argues the U.S. FDA granted tentative approvals of generic versions of Valcyte and Nexium to maintain Ranbaxy’s marketing exclusivity.
Ranbaxy Claims ‘Buyer’s Remorse’ Is Behind FDA Rescission Of ANDA Approvals
Suit argues FDA granted tentative approvals of generic versions of Valcyte and Nexium to maintain Ranbaxy’s marketing exclusivity.